Alentis Therapeutics
Alentis Therapeutics is a clinical-stage biotech developing antibody-drug conjugates and antibodies targeting Claudin-1 for cancer and fibrosis treatments. The company has raised $365M in funding, including a Series D in late 2024, and employs 70 people.
The growth story
Alentis Therapeutics grew from 16 to 70 employees between 2021 and 2026, raising $365M along the way, most recently a Series D in November 2024.
About
Alentis focuses on Claudin-1, a previously unexploited target in oncology and fibrotic diseases. Its therapies aim to modify disease progression rather than just treat symptoms, based on research from the University of Strasbourg and Inserm.
The company has secured substantial funding from life science investors like Frazier Life Sciences and Bpifrance, reaching Series D stage within five years of founding. Its 70-person team suggests a focused clinical development operation rather than large-scale manufacturing.
Founders and leadership
Research is the largest function with 7 employees, indicating a science-driven organization. The company maintains a lean structure with median tenure of 3 years, suggesting stable leadership during its rapid clinical development phase.
The Alentis Therapeutics org chart
Mark Pruzanski, MA, MD (Chief Executive Officer) leads 36 mapped leaders with 6 direct reports. Click +N to expand a team; names link to the person’s public profile.
Departments, and which ones grew
Headcount by function: Research 16 (+23% YoY), Business Development 15 (-17% YoY), Operations 7 (+17% YoY), Healthcare Services 4 (0% YoY), Finance 3 (0% YoY), Program and Project Management 3 (0% YoY).
Talent flow
Alentis recruits heavily from Roche (14 hires) and Novartis (8), drawing from Switzerland's pharmaceutical hub. Alumni have moved to various life science investors and smaller biotechs, though with limited concentration.
Most common previous employers of Alentis Therapeutics staff: Roche (14), Novartis (8), HiFiBiO Therapeutics (4), Idorsia Pharmaceuticals (4), Novartis Oncology (3), Pfizer (3). Former Alentis Therapeutics employees most often moved to Sundew (1), HTGF | High-Tech Gründerfonds (1), Bpifrance (1), Consulpharm (1), BioMedPartners (1), Morningside (1).
Alumni worth knowing
Web traffic
Traffic mix: 0% direct, 0% search, 0% social, 0% paid.
What this company is made of
Most common skills at Alentis Therapeutics: Molecular Biology (22), Pharmaceutics (21), Life Sciences (20), Biotechnology (20), Project Management (18), Oncology (18), Clinical Trials (17), Drug Discovery (16).
Where the team actually sits
Alentis Therapeutics people are concentrated in Basel, Switzerland (13), Basel Metropolitan Area (5), Basel-Country, Switzerland (5), Switzerland (3).
Search footprint
Alentis Therapeutics attracts about 88 organic search visits a month, traffic worth roughly $0K a month if bought through ads. It gained 18 ranking keywords and lost 8 in the last period.
Frequently asked
Alentis Therapeutics has 70 employees as of September 2026.
Alentis Therapeutics has raised $365M in total, most recently a Series D round in November 2024.
Alentis Therapeutics was founded in 2019 by Thomas Baumert.
Mark Pruzanski, MA, MD (Chief Executive Officer) sits at the top of Alentis Therapeutics's reporting structure, with 6 direct reports.
The most common previous employers of current Alentis Therapeutics staff are Roche (14 people), Novartis (8 people), HiFiBiO Therapeutics (4 people).
Former Alentis Therapeutics employees most often move to Sundew (1), HTGF | High-Tech Gründerfonds (1), Bpifrance (1).
Alentis Therapeutics attracts about 88 organic search visits a month, worth roughly $0K a month in equivalent ad spend.
The most common skills among Alentis Therapeutics staff are Molecular Biology, Pharmaceutics, Life Sciences, Biotechnology, Project Management.
Alentis Therapeutics staff are concentrated in Basel, Switzerland (13), Basel Metropolitan Area (5), Basel-Country, Switzerland (5).
Alentis Therapeutics has about 16 people in Research, up 23% over the past year, as of September 2026.
Alentis Therapeutics has about 15 people in Business Development, down 17% over the past year, as of September 2026.
Computed from 54 current and 24 former Alentis Therapeutics profiles, as of September 2026. Source: Crustdata.
Build this for any company
Every number on this page came from the Crustdata API. Point the MCP at a company and get the same org chart, alumni list and talent flow in one prompt.